International Journal of Drug Delivery Technology
Volume 14, Issue 2

Preparation and Evaluation of Rebamipide Ophthalmic Nanosuspension for Dry Eye Therapy

Reena Tyagi*, Vijay Bhalla

Department of Pharmaceutics, SGT University, SGT College of Pharmacy, Gurgaon, Haryana, India. 

Received: 21st October, 2023; Revised: 23rd April, 2024; Accepted: 26th April, 2024; Available Online: 25th June, 2024

ABSTRACT

Dry eye syndrome poses a therapeutic challenge due to the limited residence time of traditional treatments on the ocular surface. The commercially available rebamipide (REB) ophthalmic suspension, though approved for clinical use in dry eye patients, suffers from rapid drainage through the nasolacrimal duct, limiting its effectiveness. In this study, rebamipide nanosuspension was successfully developed by solvent-diffusion methodology and investigated for measurement of particle size, shape, surface charge, fourier-transform infrared (FTIR), differential scanning calorimetry (DSC), percentage entrapment efficiency, dissolution studies and release kinetics, ex-vivo permeability study. Results demonstrate that the optimized formulation has 196 nm particle size, surface charge of +32.5 mV, and low polydispersity. FTIR studies revealed that the drug exhibits compatibility with the excipients integrated into the formulation. DSC and X-ray diffraction (XRD) analysis revealed a decrease in the crystalline nature of the drug. Transmission electron microscope (TEM) findings indicate that rebamipide nanosuspension possesses a spherical shape, and in-vitro studies demonstrate a slower and sustained release of REB. Ex-vivo studies performed on excised goat corneas demonstrated significantly improved drug permeation compared to the suspension without inducing corneal damage.

Keywords: Nanosuspension, Rebamipide, Ocular drug delivery, Dry eye disease, Eye disorders, Ophthalmic drug delivery. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.05

How to cite this article: Tyagi R, Bhalla V. Preparation and Evaluation of Rebamipide Ophthalmic Nanosuspension for Dry Eye Therapy. International Journal of Drug Delivery Technology. 2024;14(2):644-648.

REFERENCES

  1. Lemp A. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. Eye & contact lens. 1995 Oct 1;21(4):221-32.
  2. LEMP M. Diagnosis and treatment of tear deficiency. Clin Ophthalmol. 1992;4:1-4.
  3. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS, Buznego C, Gira JP, Goldberg DF, Goldman D. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders–new strategies for diagnosis and treatment. Current opinion in ophthalmology. 2017 Jan 1;28:3-47.
  4. Phadatare SP, Momin M, Nighojkar P, Askarkar S, Singh KK. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges. Advances in Pharmaceutics. 2015 Jan 28;2015.
  5. Matsuda T, Hiraoka S, Urashima H, Ogura A, Ishida T. Preparation of an ultrafine rebamipide ophthalmic suspension with high transparency. Biological and Pharmaceutical Bulletin. 2017 May 1;40(5):665-74.
  6. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Diclofenac- loaded Eudragit S100 nanosuspension for ophthalmic delivery. Journal of microencapsulation. 2011 Feb 1;28(1):37-45.
  7. Ambhore NP, Dandagi PM, Gadad AP. Formulation and comparative evaluation of HPMC and water soluble chitosan- based sparfloxacin nanosuspension for ophthalmic delivery. Drug delivery and translational research. 2016 Feb;6:48-56.
  8. Gubbala LP , Arutla S , Venkateshwarlu V. Optimization of Composition and Process for Preparing Metaxalone Nanosuspension using Factorial Design. International Journal of Drug Delivery Technology. 2016; 6(3):79-91.
  9. Sahoo CK, Mishra AK, Moharana AK. Formulation and Evaluation of Carbamazepine Nanosuspension with the Help of Cosolvent Technique. International Journal of Drug Delivery Technology. 2022;12(2):472-475.
  10. Padmnabh, Bhatt DC. Formulation, Optimization, and Evaluation of Gliclazide loaded Nanosuspension for Dissolution Rate Enhancement. International Journal of Pharmaceutical Quality Assurance. 2023;14(4):1107-1114.
  11. Patil OA, Patil IS, Mane RU, Randive DS, Bhutkar MA, Bhinge SD. Formulation optimization and evaluation of Cefdinir nanosuspension using 23 Factorial design. Marmara Pharm J. 2018 Jan 1;22(4):587-98.
  12. Katara R, Sachdeva S, Majumdar DK. Design, characterization, and evaluation of aceclofenac-loaded Eudragit RS 100 nanoparticulate system for ocular delivery. Pharmaceutical Development and Technology. 2019 Mar 16;24(3):368-79.
  13. Manchanda S, Sahoo PK, Majumdar DK. Mucoadhesive chitosan-dextran sulfate nanoparticles of acetazolamide for ocular hypertension. Nanotechnology Reviews. 2016 Oct 1;5(5):445-53.
  14. Mohanty B, Majumdar DK, Mishra SK, Panda AK, Patnaik S. Development and characterization of itraconazole-loaded solid lipid nanoparticles for ocular delivery. Pharmaceutical development and technology. 2015 May 19;20(4):458-64.
  15. Mamatha P, Bhikshapathi DVRN. Preparation and In-vitro Evaluation of Pemigatinib Nanosponges Tablets by Box-Behnken Design. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):791-800.